Novo Nordisk A/S (NVO) is a publicly traded company in the Healthcare — Drug Manufacturers - General industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease.
Is Novo Nordisk A/S stock overvalued or undervalued in 2026?
Novo Nordisk A/S (NVO) trades at 9.8× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At the decade median (24.5×) $95 (+149 %); at its sector median (30.4×) $118 (+209 %). Note: these prices use the last twelve months' earnings, and analysts expect them to fall 15 % in 2027; at this price, its 2027 P/E would be 11.6×.
Kaplio overview: Novo Nordisk A/S
Market cap $169B · 52 weeks $35 – $64 (39 % below the high) · P/E 9.8× · 2027 expected P/E 11.6× · Dividend 4.5 % · 8 years rising · Next earnings November 4, 2026 · expected EPS $0.73 · Closing price, Oct 28 · accounts published Aug 5.
- Valuation: P/E 9.8× (cheap).
- Business: ROIC 30 % (solid).
- Balance sheet: Net debt/EBITDA 0.7× (solid).
- Earnings: 7 of 8 (on track).
Analysts expect earnings per share to fall 15 % in 2027: at this price, its 2027 P/E would be 11.6×.
What would it be worth at its usual multiples?
At the decade median (24.5×) $95 (+149 %); at its sector median (30.4×) $118 (+209 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Note: these prices use the last twelve months' earnings, and analysts expect them to fall 15 % in 2027; at this price, its 2027 P/E would be 11.6×.
What matters in pharma: 6 of 7 pass
- FCF / Net Income 28.3 %, fails.
- R&D / Revenue 16.8 %, passes.
- 5y EPS growth 20.6 %, passes.
- Gross margin 81.0 %, passes.
- ROIC 29.7 %, passes.
- Net debt / EBITDA 0.7×, passes.
- P/E vs own 10y history 9.8×, passes.
Against its peers (reference peers) — Novo Nordisk A/S: P/E 9.8×; EV/EBITDA 7.0×; ROIC 29.7 %; $169B. Pfizer Inc. (P/E 38.9×; EV/EBITDA 17.2×; ROIC 9.9 %; $168B), Amgen Inc. (P/E 28.1×; EV/EBITDA 16.1×; ROIC 14.2 %; $244B), AstraZeneca PLC (P/E 25.4×; EV/EBITDA 14.3×; ROIC 12.7 %; $263B).
Expensive or cheap against its last ten years?
P/E at each close: today 9.8× · median 24.5× · minimum 9.2× · maximum 49.9× · cheap below 19.7× · expensive above 35.6×. It has been cheaper than today only 2% of the time over its last ten years.
Dividend
solid · Yield 4.5 % ($1.73 per ADS in 2025) · Years raising it 8 · 5-year growth +22 % a year · Free cash flow coverage 1.3× · With $1,000 invested today you'd collect $45.40 a year ($3.78 a month).
Investor methods verdict
Would Buffett approve Novo Nordisk A/S today?
The Buffett Method approves Novo Nordisk A/S today: it yields 9.0% before tax; it asks for 10%. Business quality: 94 out of 100 (price not included). Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Would Peter Lynch approve Novo Nordisk A/S today?
The Lynch Method approves Novo Nordisk A/S today: P/E 9.8 with 21% growth; it asks that the P/E not exceed growth. Business quality: 78 out of 100 (price not included). Lynch classifies it as a fast grower. Kaplio assessment with data from the week of 2026-10-26; not investment advice.
Profitability
| Return on Equity | 59.09% |
| Return on Invested Capital | 29.73% |
| Return on Assets | 19.57% |
| Gross Margin | 80.65% |
| Operating Margin | 43.13% |
| Net Margin | 35.35% |
Financial Health
| Debt / Equity | 0.63 |
| Current Ratio | 0.87 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 4.23 |
Compare it with
Price Performance
| 1 month | -0.05% |
| 3 months | -18.67% |
| Year-to-date | -24.74% |
| 1 year | -25.46% |
| 3 years | -60.28% |
| 5 years | -30.47% |
| 10 years | +115.48% |
Dividend History
Paid in the last 12 months: $1.7966 per share in 2 payments.
| Date | Amount |
|---|---|
| 2026-08-17 | $0.5792 |
| 2026-03-30 | $1.2174 |
| 2025-08-18 | $0.5843 |
| 2025-03-31 | $1.1426 |
| 2024-08-16 | $0.5169 |
| 2024-03-22 | $0.9293 |
| 2023-08-18 | $0.4382 |
| 2023-03-24 | $0.5903 |
| 2022-08-12 | $0.2889 |
| 2022-03-25 | $0.5112 |
Amounts adjusted for stock splits.
Related companies: MRK · AMGN · SNY · LLY · JNJ · ABBV · AZN · PFE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of NVO: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks